Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial.
about
Multisciplinary management of patients with liver metastasis from colorectal cancerEffect of angiogenesis inhibitor bevacizumab on survival in patients with cancer: a meta-analysis of the published literature.Safety of bevacizumab in treating metastatic colorectal cancer: a systematic review and meta-analysis of all randomized clinical trials.Multidisciplinary approach of colorectal cancer liver metastases.Peri-operative chemotherapy in the management of resectable colorectal cancer pulmonary metastases.FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer.Successful treatment of conversion chemotherapy for initially unresectable synchronous colorectal liver metastasis.An update on chemotherapy of colorectal liver metastasesPrognostic value of Ki-67 expression in conversion therapy for colorectal liver-limited metastasesRandomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study.Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer.Efficacy of first-line systemic treatment in correlation with BRAF V600E and different KRAS mutations in metastatic colorectal cancer - a single institution retrospective analysisCritical appraisal of bevacizumab in the treatment of metastatic colorectal cancer.Neoadjuvant bevacizumab persistently inactivates VEGF at the time of surgery despite preoperative cessationNeoadjuvant and conversion treatment of patients with colorectal liver metastasis: the potential role of bevacizumab and other antiangiogenic agentsThe oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus.Clinical Implication of UGT1A1 Promoter Polymorphism for Irinotecan Dose Escalation in Metastatic Colorectal Cancer Patients Treated with Bevacizumab Combined with FOLFIRI in the First-line SettingUse of bevacizumab in metastatic colorectal cancer: report from the Mexican opinion and analysis forum on colorectal cancer treatment with bevacizumab (September 2009)Management of potentially resectable colorectal cancer liver metastasesTargeted therapies in colorectal cancer: surgical considerations.Systemic cytotoxic and biological therapies of colorectal liver metastases: expert consensus statementRole of bevacizumab in colorectal cancer growth and its adverse effects: a review.Bevacizumab with preoperative chemotherapy versus preoperative chemotherapy alone for colorectal cancer liver metastases: a retrospective cohort studyA phase II clinical study of mFOLFOX6 plus bevacizumab as first-line therapy for Japanese advanced/recurrent colorectal cancer patientsA clinical study of metastasized rectal cancer treatment: assessing a multimodal approach.The neoadjuvant therapy of colorectal hepatic metastases and the role of biologic sensitizing and resistance factors.Biologic modulation of chemotherapy in patients with hepatic colorectal metastases: the role of anti-VEGF and anti-EGFR antibodies.The role of bevacizumab in colorectal cancer: understanding its benefits and limitations.Multidisciplinary approach of colorectal liver metastases.Liver metastases from colorectal cancer: how to best complement medical treatment with surgical approaches.Therapeutic potential of surgery for metastatic colorectal cancer.Neoadjuvant and adjuvant therapy in relation to surgery for colorectal liver metastases.Impact of targeted neoadjuvant therapies in the treatment of solid organ tumours.Oncological management of unresectable liver metastases.Bevacizumab-based therapy in relapsed glioblastoma: rationale and clinical experience to date.The evolving role of VEGF-targeted therapies in the treatment of metastatic colorectal cancer.Monoclonal antibodies in gastrointestinal cancers.Evaluation and management of hepatic injury induced by oxaliplatin-based chemotherapy in patients with hepatic resection for colorectal liver metastasis.Panitumumab in metastatic colorectal cancer.Panitumumab in the management of patients with KRAS wild-type metastatic colorectal cancer.
P2860
Q28069575-863C9DB1-CF8A-4723-8F44-A41788743CB6Q31060162-C5752927-2133-4C49-9414-F05E8ED78B7BQ31127134-68B6D060-70E5-40F0-816B-611D248897A5Q33779859-9E34081B-DDAF-477E-8F6C-53BF0D4760A5Q34360237-E0F634C4-496F-4ADC-8426-9F2FCC945AAAQ34745831-C800BCAD-0459-4882-B6D0-EEEB61BEB749Q35069535-4FD5E3F3-F63A-4EF4-8A2A-AE861B219F5AQ35653578-DDC86B88-AAA4-4E3E-9BAA-ED402B02B669Q35666492-ED8CE54C-EEB7-4369-BAB8-AD5006D48C14Q35904219-26D646CD-DA94-4CDC-A001-84154D2D6800Q35913223-0D2C31B7-6742-41E6-9985-68E8A26AB012Q36177848-E60E7493-545B-4107-B362-A2083BA9B5D5Q36286831-D0E3C6C2-93F7-4F7C-A954-04B1C241EFC7Q36299062-312AE385-1337-4859-8414-3E64F99E3A8FQ36343047-7514B232-3EAC-4A56-9F70-37CA9B0850E8Q36349575-2E633CBF-E8C5-41D5-8F58-315E532A16C0Q36427498-44AA535D-3A4F-4F16-A312-ED61DA527117Q36649513-165679F9-4FBA-40C5-9A5C-09F4A49D9FA2Q36871770-8EAAF94A-90BA-48AA-96C1-154BAD8AB0D0Q37015697-E1809FB5-D452-47EC-AF90-3A99BD4BB2CEQ37037106-C1C394B3-6BE2-4A3F-9637-0FBA46D1A37AQ37102447-ADC35D52-6E33-4649-BDE4-C20F658DECE6Q37226458-AB63C48E-1546-4CBD-A38C-37FCABFBC388Q37272489-AC8E18A8-AFA0-4F04-B75F-D8F0EF442D57Q37601319-848E092B-C299-4714-8E8B-AD750CE07259Q37821836-6E5AB3E7-E707-4FC0-9DB4-21C613E9C6E6Q37821843-7024A796-323C-4023-866C-C57B71F8BDA5Q37833645-EC224AF3-DC8E-48D8-BF07-F0CC7452D164Q37942736-E58A6B03-574F-45EB-87EB-6D356EFDF55BQ37951604-76157AA5-D166-45CE-8550-2396E408DC90Q37969826-9A849EC8-D466-43BD-8081-D45D219F47ACQ37969833-CF5D02F9-24E9-4F00-B8C2-94E0FB2C976EQ38061098-7E2AC960-F1D2-43B9-AE71-AC1A0E95908DQ38064752-47DFF807-BEDB-46F3-AE0B-512B4EB3FA17Q38068203-CBB5BEA1-DA5A-4B0A-8CB6-361A747C7F0FQ38083816-89F71445-F971-4FCE-AD9D-8EF13BF250C9Q38084684-26F781F5-D953-41FF-9F6D-3022C57EA339Q38095594-64B7CE21-4709-4F6B-918A-AC1AED18A9F3Q38117191-2C275C3F-93D8-4784-B6F5-359B7F1671F2Q38175030-4955DB2E-5709-46E6-81C7-B909632CC743
P2860
Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Surgery with curative-intent i ...... mised phase-III NO16966 trial.
@en
Surgery with curative-intent i ...... mised phase-III NO16966 trial.
@nl
type
label
Surgery with curative-intent i ...... mised phase-III NO16966 trial.
@en
Surgery with curative-intent i ...... mised phase-III NO16966 trial.
@nl
prefLabel
Surgery with curative-intent i ...... mised phase-III NO16966 trial.
@en
Surgery with curative-intent i ...... mised phase-III NO16966 trial.
@nl
P2093
P2860
P921
P356
P1476
Surgery with curative-intent i ...... mised phase-III NO16966 trial.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.BJC.6605259
P407
P577
2009-10-01T00:00:00Z